1 Livingston G, et al. Dementia prevention, intervention, and care. Lancet. 2017 Jul 19. pii:S0140 6736(17)31363–6.
2 http://www.alzheimer-europe.org/Research/European-Collaboration-on-Dementia/Prevalence-of-dementia/Prevalence-of-dementia-in-Europe.
3 Dubois B, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614–29.
4 Matthews FE, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun. 2016 Apr;19;7:11398.
5 Jack CR Jr, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207–16.
6 Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010 Dec;24;330(6012):1774.
7 Dubois B, et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292–323.
9 https://www.bag.admin.ch/bag/de/home/themen/strategien-politik/nationale-gesundheitsstrategien/nationale-demenzstrategie.html
10 Annoni JM, Chouiter L, Démonet JF. Rev Med Suisse. Troubles cognitifs liés au vieillissement: évolution récente des concepts et stratégies diagnostiques. 2016 Apr;20;12(515):774–9.
11 Daher O, Nguyen S, Smith C, Büla C, Démonet JF. Les pathologies démentielles: Prise en charge et prévention. Rev Med Suisse. 2016 Apr;20;12(515):799–802.
12 Howard R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015 Dec;14(12):1171–81.
13 Knapp M et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017 Dec;32(12):1205–16.
14 Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255–63.
15 Abbott A, Dolgin E. Failed Alzheimer’s trial does not kill leading theory of disease. Nature. 2016 Nov;23;540(7631):15–6.
16 Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017 Aug;16(8):661–76.